No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
kurosbio.comNo one on the platform currently holds KURN.SW.
No tracked institution reports a position in KURN.SW as of their last filing.
No one on the platform has traded KURN.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.6% | — | — | — | ||
| Rev. Growth % | 60.5% | 97.5% | ||||
| Profit Margin % | 1.7% | -36.0% | -748.8% | |||
| Free Cash Flow Margin % | -2.0% | -22.4% | -579.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $170M | +44.0% | $0.29 | $0.16–$0.43 | — | 3 |
| 2027 | $219M | +29.3% | $0.54 | $0.26–$0.65 | — | 4 |
| 2028 | $272M | +23.8% | $0.90 | $0.41–$1.18 | — | 3 |
| 2029 | $322M | +18.6% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| KURN.SWKuros Biosciences AG | $17.84 | -2.09% | $704M | — |
| AEVS.SWAevis Victoria S.A. | $12.70 | +0.40% | $1.1B | — |
| BION.SWBB Biotech AG | $52.40 | -0.19% | $2.9B | — |
| BSLN.SWBasilea Pharmaceutica AG | $66.10 | -0.90% | $818M | — |
| COPN.SWCosmo Pharmaceuticals N.V. | $58.70 | +0.00% | $1.0B | — |
| IDIA.SWIdorsia Ltd | $5.00 | -0.04% | $1.3B |
Source: Financial Modeling Prep · peers by sector/industry
| — |
| MED.SWMedartis Holding AG | $83.90 | +0.60% | $1.0B | — |